Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
204
datasets available to search
ShareScore release 0.9.0
Dataset results
204 results for “chronic migraine”
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
ClinicalTrials.gov study NCT03855137. IPD Sharing: YES. Countries: 17. Publications: 10.
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
ClinicalTrials.gov study NCT03867201. IPD Sharing: YES. Countries: 9. Publications: 1.
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
ClinicalTrials.gov study NCT03828539. IPD Sharing: YES. Countries: 1. Publications: 2.
Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine
<p>This dataset comprises the findings obtained in the study aimed at investigating the effects of URB937, a peripherally restricted fatty-acid amide hydrolase (FAAH) inhibitor, in two rat models that capture aspects of acute and chronic migraine, and are based on single or repeated administration of the vasodilating drug, nitroglycerin (NTG). The orofacial nocifensive behavior and mRNA levels of neuropeptides and pro-inflammatory cytokines along with tissue levels of anandamide and palmitoylethanolamide (PEA) were measured in trigeminal ganglia and medulla.</p> <p>All evaluations were made in rats that received a single injection of URB937 (1 mg/kg i.p.) either before or after NTG administration (10 mg/kg, i.p.) within the acute model, or daily URB937 (1 mg/kg i.p.) injections within the NTG (5 mg/kg, i.p.) chronic model. In the acute migraine model, we also investigated the effect of subtype-selective antagonist for cannabinoid receptors 1 and 2 (AM251 and AM630, respectively). Specifically, we achieved the following evaluations:</p> <p>1. Measurement of AEA and PEA levels: medulla and trigeminal ganglia were homogenized in cold methanol (2 ml) containing AEA-d4 and PEA-d4 as internal standards. After extraction the lipids were measured using a Xevo TQ UPLC-MS/MS system equipped with a reversed-phase BEH C18 column (2.1 × 50 mm, 1.7 μm particle size) (Waters, Milford, USA).</p> <p>2. Pain-related behavior in the orofacial formalin test: the face rubbing was measured counting the seconds the animal spent grooming the injected area (upper lip, lateral to the nose) with the ipsilateral forepaw or hindpaw 0–6 min (Phase I) or 12–45 min (Phase II) after formalin injection (50 µl, s.c.). The observation time was divided into 15 blocks of 3 min each.</p> <p>3. mRNA expression levels: calcitonin gene-related peptide (CGRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) mRNA were evaluated in in medulla and trigeminal ganglia. mRNA levels were measured by rt-PCR. All samples were assayed in triplicate and gene expression levels were calculated according to 2−∆∆Ct = 2− (∆Ct gene − ∆Ct housekeeping gene) formula by using Ct (cycle threshold) values.</p>
Antagonism of CGRP Receptor: Central and Peripheral Mechanisms and Mediators in an Animal Model of Chronic Migraine
<p>This dataset includes the findings obtained in the study aimed at investigating in more depth the interplay between the neuropeptide CGRP and the inflammatory mediators within the mechanisms of neuronal sensitization in an animal model of chronic migraine, using olcegepant as a pharmacological probe. Male Sprague-Dawley rats were exposed to nitroglycerin (NTG, 10 mg/kg, i.p.) or NTG vehicle and treated with the CGRP receptor antagonist olcegepant (1 or 2 mg/kg, i.p.) or vehicle (1 ml/kg, i.p.) 1h before the orofacial formalin test. Additionally, sets of rats received NTG (5 mg/kg, i.p.) or vehicle (equivalent volume) co-administered with olcegepant (2 mg/kg i.p.) or its vehicle every other day over a 9-day period. Twenty-four hours after the last injection of NTG (or vehicle), a first set of rats underwent the orofacial formalin test. In a second set, we evaluated the gene expression of CGRP and gene and protein expression of pro-inflammatory cytokines in specific areas involved in migraine pain. We also assessed the CGRP and cytokine levels in serum.</p> <p>The in vivo and ex vivo assessments were:</p> <p>1) Pain-related behavior in the orofacial formalin test: the face rubbing was measured counting the seconds the animal spent grooming the injected area (upper lip, lateral to the nose) with the ipsilateral forepaw or hindpaw 0–6 min (Phase I) or 12–45 min (Phase II) after formalin injection (50 µl, s.c.). The observation time was divided into 15 blocks of 3 min each.</p> <p>2) mRNA expression levels: CGRP, tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), transient receptor potential ankyrin 1 (TRPA1) in cervical spinal cord (CSC), medulla-pons and trigeminal ganglia (TGs). mRNA levels were measured by rt-PCR. The same RNA was used for miRNAs (Mir-34a-5p, Mir-382-5p, Mir-155-5p) extraction in the same areas. All samples were assayed in triplicate and gene expression levels were calculated according to 2−∆∆Ct = 2− (∆Ct gene − ∆Ct housekeeping gene) formula by using Ct (cycle threshold) values.</p> <p>3) Pro-inflammatory cytokines in medulla-pons, CSC and TGs were evaluated using ELISA procedure. CGRP, TNF-alpha and IL-1beta serum levels were measured using commercial ELISA kits.</p> <p>Results in brief</p> <p>Olcegepant attenuated nitroglycerin-induced trigeminal hyperalgesia in the second phase of the orofacial formalin test. Interestingly, it also reduced gene expression and protein levels of CGRP, pro-inflammatory cytokines, inflammatory-associated miRNAs (miR-155-5p, miR-382-5p and miR-34a-5p) and TRPA1 channels in medulla-pons area, cervical spinal cord and trigeminal ganglia. Similarly, olcegepant reduced the NTG-induced increase of CGRP and inflammatory.</p>
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
ClinicalTrials.gov study NCT01516892. IPD Sharing: Not stated. Countries: 3. Publications: 4.
"Follow the Sutures". A New Procedure for Injection of Botulinum Toxin for Chronic Migraine
ClinicalTrials.gov study NCT03543254. IPD Sharing: NO. Countries: 1. Publications: 1.
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
ClinicalTrials.gov study NCT02974153. IPD Sharing: Not stated. Countries: 13. Publications: 14.
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
ClinicalTrials.gov study NCT04437433. IPD Sharing: YES. Countries: 1. Publications: 0.
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
ClinicalTrials.gov study NCT04161807. IPD Sharing: NO. Countries: 2. Publications: 1.
BOTOX® Prophylaxis in Patients With Chronic Migraine
ClinicalTrials.gov study NCT01432379. IPD Sharing: Not stated. Countries: 4. Publications: 1.
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
ClinicalTrials.gov study NCT01686581. IPD Sharing: Not stated. Countries: 7. Publications: 3.
A Multicenter Assessment of ALD403 in Chronic Migraine
ClinicalTrials.gov study NCT02275117. IPD Sharing: Not stated. Countries: 4. Publications: 3.
Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
ClinicalTrials.gov study NCT02191579. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
ClinicalTrials.gov study NCT03303079. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Assessment of LBR-101 In Chronic Migraine
ClinicalTrials.gov study NCT02021773. IPD Sharing: Not stated. Countries: 1. Publications: 4.
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
ClinicalTrials.gov study NCT01662492. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
ClinicalTrials.gov study NCT02174861. IPD Sharing: Not stated. Countries: 10. Publications: 6.
Effects of Online Mindfulness Therapy on Pain and Stress in Adults With Chronic Migraine and Adverse Childhood Experiences
ClinicalTrials.gov study NCT07033520. IPD Sharing: NO. Countries: 1. Publications: 5.
Calcitonin Gene-related Peptide Levels in Chronic Migraine
ClinicalTrials.gov study NCT01071096. IPD Sharing: Not stated. Countries: 1. Publications: 7.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.